Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treg and Tcon Infusion in Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT
NCT05088356Phase 1Active, not recruiting
- Sponsor
- Stanford University
- Start
- Sep 2021
- Primary completion
- May 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial in acute leukemia, chronic myelogenous leukemia (CML), myelodysplastic syndrome (MDS) and 1 more (7 arms), sponsored by Stanford University. Primary endpoints: GVHD-free relapse-free survival at 12 months, Overall survival at 2 years and 3 more. Started Sep 2021; status: active, not recruiting.
02
Conditions
acute leukemiachronic myelogenous leukemia (CML)myelodysplastic syndrome (MDS)myeloproliferative neoplasms (MPN)
Beyond the preview
Go deeper on NCT05088356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05088356.